![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-1.jpg\")
<\/p>\nEdition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n
General Notices<\/p>\n
(Ph. Eur. monograph 2578)<\/p>\n
<\/p>\n
C9H9Cl2N5S\u00a0 \u00a0290.2\u00a0\u00a0 64461-82-1<\/p>\n
Action and use<\/p>\n
Alpha2-adrenoceptor agonist; skeletal muscle relaxant.<\/p>\n
Ph Eur<\/p>\n
5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride.<\/p>\n
Content<\/p>\n
98.0 per cent to 102.0 per cent (dried substance).<\/p>\n
White or yellowish-white, crystalline powder.<\/p>\n
Soluble in water, very slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride.<\/p>\n
A. Infrared absorption spectrophotometry (2.2.24). Comparison tizanidine hydrochloride CRS.<\/p>\n
B. Solution S (see Tests) gives reaction (a) of chlorides (2.3.1).<\/p>\n
Dissolve 0.5 g in carbon dioxide-free water R and dilute to 50 mL with the same solvent.<\/p>\n
pH (2.2.3)<\/p>\n
3.7 to 5.0 for solution S.<\/p>\n
Thin-layer chromatography (2.2.27).<\/p>\n
Test solution Dissolve 0.200 g of the substance to be examined in methanol R and dilute to 5.0 mL with the same solvent.<\/p>\n
Reference solution Dissolve 8.0 mg of ethylenediamine R (impurity H) in methanol R and dilute to 100.0 mL with the same solvent.<\/p>\n
Plate TLC cellulose plate R.<\/p>\n
Mobile phase glacial acetic acid R, water R, methanol R (1:25:75 V\/V\/V).<\/p>\n
Application 5 \u03bcL.<\/p>\n
Development Over 1\/2 of the plate.<\/p>\n
Drying In a current of cold air.<\/p>\n
Detection Spray with a mixture of 15 volumes of a 20 g\/L solution of ninhydrin R in glacial acetic acid R and 85 volumes of butanol R, then heat at 100 \u00b0C for 5 min.<\/p>\n
Relative retention with reference to tizanidine (RF = about 0.8): impurity H = about 0.3.<\/p>\n
Limit:<\/p>\n
\u2014 impurity H: any spot due to impurity H is not more intense than the corresponding spot in the chromatogram obtained with the reference solution (0.2 per cent).<\/p>\n
Liquid chromatography (2.2.29).<\/p>\n
Test solution Dissolve 30.0 mg of the substance to be examined in mobile phase A, using sonication if necessary, and dilute to 25.0 mL with mobile phase A. Dilute 5.0 mL of the solution to 50.0 mL with mobile phase A.<\/p>\n
Reference solution (a) Dissolve 3 mg of tizanidine impurity B CRS in mobile phase A and dilute to 25.0 mL with mobile phase A. Dilute 1.0 mL of the solution to 100.0 mL with mobile phase A. Dilute 1.0 mL of this solution to 10.0 mL with the test solution.<\/p>\n
Reference solution (b) Dilute 1.0 mL of the test solution to 100.0 mL with mobile phase A. Dilute 1.0 mL of this solution to 10.0 mL with mobile phase A.<\/p>\n
Reference solution (c) Dissolve 30.0 mg of tizanidine hydrochloride CRS in mobile phase A, using sonication if necessary, and dilute to 25.0 mL with mobile phase A. Dilute 5.0 mL of the solution to 50.0 mL with mobile phase A.<\/p>\n
Column:<\/p>\n
\u2014 size: l = 0.15 m, \u00d8 = 4.6 mm;<\/p>\n
\u2014 stationary phase: end-capped octadecylsilyl silica gel for chromatography R (3.5 \u03bcm);<\/p>\n
\u2014 temperature: 50 \u00b0C.<\/p>\n
Mobile phase:<\/p>\n
\u2014 mobile phase A: mix 18 volumes of acetonitrile R1 and 82 volumes of a 3.86 g\/L solution of sodium pentanesulfonate monohydrate R previously adjusted to pH 3.0 with phosphoric acid R;<\/p>\n
\u2014 mobile phase B: mix 20 volumes of a 3.86 g\/L solution of sodium pentanesulfonate monohydrate R previously adjusted to pH 3.0 with phosphoric acid R and 80 volumes of acetonitrile R1.<\/p>\n
| Time (min)<\/td>\n | Mobile phase A (per cent V\/V)<\/td>\n | Mobile phase B (per cent V\/V)<\/td>\n<\/tr>\n |
| 0 – 15<\/td>\n | 100<\/td>\n | 0<\/td>\n<\/tr>\n |
| 15 – 25<\/td>\n | 100 \u2192 0<\/td>\n | 0 \u2192 100<\/td>\n<\/tr>\n |
| 25 – 27<\/td>\n | 0<\/td>\n | 100<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Flow rate 0.6 mL\/min.<\/p>\n Detection Spectrophotometer at 230 nm.<\/p>\n Injection 10 \u03bcL of the test solution and reference solutions (a) and (b).<\/p>\n Identification of impurities Use the chromatogram obtained with reference solution (a) to identify the peak due to impurity B.<\/p>\n Relative retention With reference to tizanidine (retention time = about 6 min): impurity B = about 1.3.<\/p>\n System suitability Reference solution (a):<\/p>\n \u2014 resolution: minimum 4.0 between the peaks due to tizanidine and impurity B.<\/p>\n Calculation of percentage contents:<\/p>\n \u2014 for each impurity, use the concentration of tizanidine hydrochloride in reference solution (b).<\/p>\n Limits:<\/p>\n \u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n \u2014 total: maximum 0.2 per cent;<\/p>\n \u2014 reporting threshold: 0.05 per cent.<\/p>\n Loss on drying (2.2.32)<\/p>\n Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 \u00b0C.<\/p>\n Sulfated ash (2.4.14)<\/p>\n Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n ASSAY<\/h2>\nLiquid chromatography (2.2.29) as described in the test for related substances with the following modification.<\/p>\n Injection Test solution and reference solution (c).<\/p>\n Calculate the percentage content of C9H9Cl2N5S taking into account the assigned content of tizanidine hydrochloride CRS.<\/p>\n IMPURITIES<\/h2>\nSpecified impurities H.<\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A, B, C, D, E, F, G, I.<\/p>\n
A. N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine,<\/p>\n
B. N-(5-chloro-2,1,3-benzothiadiazol-4-yl)thiourea,<\/p>\n
C. 1,1\u2032-ethane-1,2-diylbis[3-(5-chloro-2,1,3-benzothiadiazol-4-yl)guanidine],<\/p>\n
D. methyl N-(5-chloro-2,1,3-benzothiadiazol-4-yl)carbamimidothioate,<\/p>\n
E. 5-chloro-2,1,3-benzothiadiazol-4-amine,<\/p>\n
F. 1,3-bis(5-chloro-2,1,3-benzothiadiazol-4-yl)-1-(4,5-dihydro-1H-imidazol-2-yl)guanidine,<\/p>\n
G. (5-chloro-2,1,3-benzothiadiazol-4-yl)cyanamide,<\/p>\n
H. ethane-1,2-diamine (ethylenediamine),<\/p>\n
I. 4-methylbenzenesulfonic acid (p-toluenesulfonic acid).<\/p>\n Ph Eur<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) General Notices (Ph. Eur. monograph 2578) C9H9Cl2N5S\u00a0 \u00a0290.2\u00a0\u00a0 64461-82-1 Action and use Alpha2-adrenoceptor agonist; skeletal muscle relaxant. Ph Eur DEFINITION 5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride. Content 98.0 per cent to 102.0 per cent (dried substance). CHARACTERS Appearance White or yellowish-white, crystalline powder. Solubility Soluble in water, very slightly soluble in ethanol…<\/p>\n","protected":false},"author":5,"featured_media":31301,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-31290","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=31290"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31290\/revisions"}],"predecessor-version":[{"id":31304,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31290\/revisions\/31304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/31301"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=31290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=31290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=31290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} |
![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-2.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-3.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-5.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-4.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-6.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-7.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-8.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-9.jpg\")
<\/p>\n![\"\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/Tizanidine-Hydrochloride-111.jpg\")
<\/p>\n